SDS Number 127265 Approved/Revised 13-Dec-2006 Version 6
STANBACK HEADACHE POWDERS
Material
SAFETY DATA SHEET
1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE
COMPANY/UNDERTAKING
Material STANBACK HEADACHE POWDERS
STANBACK HEADACHE POWDERS (US) * FORMULA NO. B1816 * ASPIRIN,
Synonyms
CAFFEINE AND SALICYLAMIDE, FORMULATED PRODUCT
GlaxoSmithKline, Corporate Environment, Health & Safety
Company Name
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information: +44-20-8047-5000
Transport Emergency (EU) +44-1865-407333
Medical Emergency +1-612-221-3999, Ext 221
Information and Advice: US number, available 24 hours
Multi-language response
GlaxoSmithKline, Corporate Environment, Health & Safety
One Franklin Plaza, 200 N 16th Street
Philadelphia, PA 19102-1225 US
US General Information: +1-888-825-5249
Transport Emergency (non EU) +1-703-527-3887
US number, available 24 hours
Multi-language response
2. COMPOSITION / INFORMATION ON INGREDIENTS
Percentage
Ingredients CAS RN
ASPIRIN 68.4
50-78-2
SALICYLAMIDE 21
65-45-2
CAFFEINE 3.4
58-08-2
NON-HAZARDOUS INGREDIENTS 7.2
Unassigned
3. HAZARDS IDENTIFICATION
Assume that this product is capable of sustaining combustion.
Fire and Explosion
* Health Eye irritant. Skin irritant.
Exposure might occur via eyes; skin; ingestion.
Health effects information is based on hazards of components.
* Environment Harmful to aquatic organisms.
4. FIRST-AID MEASURES
Page 1 / 6
SDS Number 127265 Approved/Revised 13-Dec-2006 Version 6
STANBACK HEADACHE POWDERS
Material
Ingestion Never attempt to induce vomiting. Do not attempt to give any solid or liquid
by mouth if the exposed subject is unconscious or semi-conscious. Wash
out the mouth with water. If the exposed subject is fully conscious, give
plenty of water to drink. Obtain medical attention.
* Inhalation Physical form suggests that risk of inhalation exposure is negligible.
Skin Contact Using appropriate personal protective equipment, remove contaminated
clothing and flush exposed area with large amounts of water. Obtain
medical attention if skin reaction occurs, which may be immediate or
delayed.
Eye Contact Wash immediately with clean and gently flowing water. Continue for at least
15 minutes. Obtain medical attention.
NOTES TO HEALTH PROFESSIONALS
* Medical Treatment Medical treatment in cases of overexposure should be treated as an
overdose of aspirin . Treat according to locally accepted protocols. For
additional guidance, refer to the local poison control information centre.
Medical Conditions None for occupational exposure.
Caused or Aggravated
by Exposure
Antidotes No specific antidotes are recommended.
5. FIRE-FIGHTING MEASURES
Fire and Explosion The combustibility of the product is not known, however the packaging is
combustible.
Hazards
Extinguishing Media Water or foam extinguishers are recommended.
Carbon dioxide or dry powder extinguishers may be ineffective.
Special Firefighting For single units (packages): No special requirements needed.
For larger amounts (multiple packages/pallets) of product: Since toxic,
Procedures
corrosive or flammable vapours might be evolved from fires involving this
product and associated packaging, self contained breathing apparatus and
full protective equipment are recommended for firefighters.
If possible, contain and collect firefighting water for later disposal.
Hazardous Combustion Toxic, corrosive or flammable thermal decomposition products are
expected when the product is exposed to fire.
Products
6. ACCIDENTAL RELEASE MEASURES
Personal Precautions Wear protective clothing and equipment consistent with the degree of
hazard.
Environmental Precautions For large spills, take precautions to prevent entry into waterways, sewers, or
surface drainage systems.
Clean-up Methods Collect and place it in a suitable, properly labelled container for recovery or
disposal.
Decontamination No specific decontamination or detoxification procedures have been
identified for this product.
Procedures
7. HANDLING AND STORAGE
HANDLING
General Requirements No special control measures required for the normal handling of this
product. Normal room ventilation is expected to be adequate for routine
handling of this product.
STORAGE No storage requirements necessary for occupational hazards. Follow
product information storage instructions to maintain efficacy.
Page 2 / 6
SDS Number 127265 Approved/Revised 13-Dec-2006 Version 6
STANBACK HEADACHE POWDERS
Material
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
ASPIRIN
INGREDIENT
1
GSK Occupational
Hazard Category
GSK Occupational 3000 mcg/m3 (8 HR TWA)
Exposure Limit
CAFFEINE
INGREDIENT
2
GSK Occupational
Hazard Category
GSK Occupational 200 mcg/m3 (8 HR TWA)
Exposure Limit
PERSONAL PROTECTIVE EQUIPMENT
* Eye Protection Wear approved safety glasses with side shields if eye contact is possible.
* Other Equipment or Wear appropriate clothing to avoid skin contact. Wash hands and arms
thoroughly after handling.
Procedures
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
White.
Colour
Powder.
Physical Form
10. STABILITY AND REACTIVITY
Stability This product is expected to be stable.
Conditions to Avoid None for normal handling of this product.
11. TOXICOLOGICAL INFORMATION
* Oral Toxicity Adverse effects might occur following ingestion.
* Inhalation Toxicity Overexposure may result in irritation of the respiratory tract.
Skin Effects Irritation might occur following direct contact.
Eye Effects Irritation might occur following direct contact with eyes.
* Target Organ Effects Adverse effects might occur in the following organ(s) following
overexposure: impaired blood coagulation.
* Sensitisation Unlikely to be a strong sensitiser in humans.
Genetic Toxicity Not expected to be genotoxic under occupational exposure conditions.
Carcinogenicity No components are listed as carcinogens by GSK, IARC, NTP or US
OSHA. Not expected to produce cancer in humans under occupational
exposure conditions.
* Reproductive Effects Not expected to produce adverse effects on fertility or development under
occupational exposure conditions. No adverse effects have been reported
following extensive use or exposure in humans.
* Pharmacological Effects This preparation contains ingredient(s) with the following activity: a
non-steroidal anti-inflammatory substance.
Other Adverse Effects Overexposure in the workplace might have the following effects: impaired
blood coagulation; symptoms of hypersensitivity (such as skin rash, hives,
itching, and/or difficulty breathing).
12. ECOLOGICAL INFORMATION
Page 3 / 6
SDS Number 127265 Approved/Revised 13-Dec-2006 Version 6
STANBACK HEADACHE POWDERS
Material
* Summary This product contains an active ingredient that has been tested and which
may be harmful if released directly to the environment. Appropriate
precautions should be taken to limit release of this material to the
environment. Local regulations and procedures should be consulted prior to
environmental release.
13. DISPOSAL CONSIDERATIONS
Disposal Collect for recycling or recovery if possible. The disposal method for
rejected products/returned goods must ensure that they cannot be re-sold or
Recommendations
re-used.
Regulatory Requirements Observe all local and national regulations when disposing of this product.
14. TRANSPORT INFORMATION
The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only
authorised persons trained and competent in accordance with appropriate national and international
regulatory requirements may prepare dangerous goods for transport.
UN Classification and Labelling
Transportation and shipping of this product is not restricted. It has no known,
Transport Information
significant hazards requiring special packaging or labelling for air, maritime, US
or European ground transport purposes.
15. REGULATORY INFORMATION
The information included below is an overview of the major regulatory requirements. It should not be
considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.
EU Classification and Labelling
Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal
product, cosmetic product or medical device.
US OSHA Standard (29 CFR Part 1910.1200)
Classification Exempt when packaged for sale to consumers in a retail establishment.
Other US Regulations
TSCA Status Exempt
16. OTHER INFORMATION
References GSK Hazard Determination
Date Approved/Revised 13-Dec-2006 SDS Version Number 6
SDS Sections Updated
Sections Subsections
ECOLOGICAL INFORMATION Activated Sludge Respiration
Adsorption
Algal
Algal Degradation
Bioaccumulation
Biodegradation
Crustacea
Daphnid
Distribution
Earthworm
Ecotoxicity
Page 4 / 6
SDS Number 127265 Approved/Revised 13-Dec-2006 Version 6
STANBACK HEADACHE POWDERS
Material
SDS Sections Updated
Sections Subsections
ECOLOGICAL INFORMATION EHAC Notation
Fish
GSK Environmental Hazard Category
Hydrolysis
Microbial Growth Inhibition
Microtox
Mobility
Other Adverse Effects
Other Species - Aquatic
Other Species - Terrestrial
Partitioning
Persistence/Degradation
Photolysis
Solubility
Summary
Volatility
EXPOSURE CONTROLS / PERSONAL PROTECTION Administrative
Containment
Exposure Controls
Eye Protection
Gloves
Occupational Hygiene Air Monitoring Methods
Occupational Hygiene Surface Monitoring Method
Other Equipment or Procedures
Other Exposure Limits
Other Information
Other Protective Equipment
Respirators
Surface Exposure Target
Ventilation
FIRST-AID MEASURES Antidotes
Eye Contact
Health Surveillance Procedures
Ingestion
Inhalation
Medical Conditions Caused or Aggravated by
Exposure
Medical Treatment
Skin Contact
HAZARDS IDENTIFICATION Conditions Aggravated by Exposure
Environment
Eye Contact
Health
Ingestion
Inhalation
Overview
Skin Contact
Summary
Page 5 / 6
SDS Number 127265 Approved/Revised 13-Dec-2006 Version 6
STANBACK HEADACHE POWDERS
Material
SDS Sections Updated
Sections Subsections
TOXICOLOGY INFORMATION Carcinogenicity
Eye Effects
Genetic Toxicity
Inhalation Toxicity
Oral Toxicity
Other Adverse Effects
Pharmacological Effects
Reproductive Effects
Sensitisation
Skin Toxicity
Target Organ Effects
The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate
as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the
responsibility of the user to determine the applicability of this information and the suitability of the material
or product for any particular purpose.
Page 6 / 6
|